4.2 Article

Lactoferrin Inhibits IL-1 beta-Induced Chondrocyte Apoptosis Through AKT1-Induced CREB1 Activation

Journal

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
Volume 36, Issue 6, Pages 2456-2465

Publisher

KARGER
DOI: 10.1159/000430206

Keywords

Lactoferrin; Osteoarthritis; Chondrocyte; Apoptosis

Funding

  1. National Natural Science Foundation of China [81301566]
  2. Shanghai Municipal Public Health and Family Planning Commission [2013040]
  3. Shanghai Municipal Science and Technology Commission [134119b1400]

Ask authors/readers for more resources

Background/Aims: Chondrocyte apoptosis is largely responsible for cartilage degeneration in osteoarthritis (OA). Interleukin-1 beta (IL-1 beta) is widely used as a chondrocyte apoptosis-inducing agent, while lactoferrin (LF) is an anabolic reagent which has the potential to inhibit chondrocyte apoptosis. We assessed the effects of LF on cartilage degeneration in IL-1 beta-induced chondrocytes and in a rat model of OA, and explored the potential molecular mechanisms involved. Methods: Human articular chondrocytes (HACs) were treated with IL-1 beta alone or in combination with LF. MTT and flow cytometric assays were used to detect changes after treatment with LF. Western blotting was used to examine the relevant molecules regulating apoptosis. Results: We found that IL-1 beta reduced the viability of HACs, whereas 200 mu g/mL of LF significantly counteracted the inhibitory effect of IL-1 beta. LF significantly inhibited IL-1 beta-induced HAC apoptosis. The protein expression of the apoptotic markers Caspase-3 and PARP was also significantly reduced in the LF treatment group when analyzed by western blotting. Furthermore, we found that LF triggered CREB1 phosphorylation in IL-1 beta-induced HAC apoptosis through AKT1 signaling. In addition, LF promoted the repair of articular cartilage damage in a rat OA model with elevated p-CREB levels. Conclusions: These studies suggest that LF has an anti-apoptotic effect on IL-1 beta-induced chondrocytes, and thus may be a promising novel therapeutic agent for OA. Copyright (C) 2015 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available